Vogt-Koyanagi-Harada disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C.
10.3350/kjhep.2011.17.1.61
- Author:
Jae Hee LIM
1
;
Yun Nah LEE
;
Young Seok KIM
;
Sang Gyune KIM
;
Seung Won JEONG
;
Jae Young JANG
;
Hong Soo KIM
;
Sae Hwan LEE
;
Tae Kwann PARK
Author Information
1. Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Bucheon, Korea. liverkys@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Vogt-Koyanagi-Harada disease;
Interferon-alpha2b;
Chronic hepatitis C
- MeSH:
Anti-Inflammatory Agents/therapeutic use;
Antiviral Agents/*adverse effects/therapeutic use;
Drug Therapy, Combination;
Female;
Fluorescein Angiography;
Hepatitis C, Chronic/*drug therapy;
Humans;
Interferon Alfa-2b/*adverse effects/therapeutic use;
Magnetic Resonance Imaging;
Middle Aged;
Polyethylene Glycols/*adverse effects/therapeutic use;
Prednisolone/therapeutic use;
Ribavirin/*adverse effects/therapeutic use;
Tomography, X-Ray Computed;
Uveomeningoencephalitic Syndrome/*diagnosis/drug therapy/etiology
- From:The Korean Journal of Hepatology
2011;17(1):61-65
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vogt-Koyanagi-Harada (VKH) disease is a multisystem syndrome characterized by ocular (uveitis and retinal detachment), neurological (headache, tinnitus, and meningitis), and integumentary (vitiligo, alopecia, and poliosis) involvement. Although the pathogenesis of VKH disease is not well understood, an autoimmune T-cell response to a melanocyte-associated antigen is considered to be a cause of VKH disease. The complex immunological response to interferon and ribavirin may induce or exacerbate the autoimmune condition; however, VKH disease is a very rare complication associated with interferon therapy in chronic hepatitis C. We report a case of VKH disease occurring during pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C.
